| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/01/2002 | CN1083842C [1,2,4] triazolo [4,3-a] quinoxalinone derivs., their preparation and use |
| 05/01/2002 | CN1083838C Novel imidazole derivs., method for preparing same, use as medicine, and pharmaceutical compositions contg. same |
| 05/01/2002 | CN1083834C Nipecotic acid derivs. as antithrombic compounds |
| 05/01/2002 | CN1083833C Sulfur-substd. azetidinone compounds useful as hypocholesterolemic agents |
| 05/01/2002 | CN1083830C Substd. benzamidines, their production and their use as medicaments |
| 05/01/2002 | CN1083723C Thrombolytic and hypotensor pill |
| 05/01/2002 | CN1083715C Use of insulin sensitisers for treating renal diseases |
| 04/30/2002 | US6380430 Biphenyl derivatives |
| 04/30/2002 | US6380258 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 04/30/2002 | US6380251 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380250 Therapy of ocular hypertension which comprises administering cyclopentane heptan(ene)oic acid or its 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives |
| 04/30/2002 | US6380238 Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands |
| 04/30/2002 | US6380226 For therapy of migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with a vascular disorder, depression, anxiety, an eating disorder, obesity, drug abuse, hypertension and emesis |
| 04/30/2002 | US6380220 Therapy of neurodegenerative diseases and neuronal injuries which are casued by ischemia, trauma or massive hemorrhages |
| 04/30/2002 | US6380211 For treating diabetes |
| 04/30/2002 | US6380204 Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist activity |
| 04/30/2002 | US6380200 Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications |
| 04/30/2002 | US6380195 Including (methylenedioxyphenyl)cyclopenteno(1,2-b)pyridine derivatives |
| 04/30/2002 | US6380191 Arylthiazolidinedione and aryloxazolidinedione derivatives |
| 04/30/2002 | US6380184 For increased production of wool, milk, and meat by treating animals with therapeutically effective amount of compound |
| 04/30/2002 | US6380170 Nucleic acid construct for the cell cycle regulated expression of structural genes |
| 04/30/2002 | US6380162 Ice inhibiting peptides |
| 04/30/2002 | US6379926 Polynucleotides encoding chemokine β-6 antagonists |
| 04/30/2002 | US6379913 A polypeptide encoding an amino acid sequence; prevention and therapy for diabetes, inflammatory glomerulonephritis, ischemis renal failure, artherosclerosis, coronary vasoconstriction and ischemic heart disease |
| 04/30/2002 | US6379699 Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety |
| 04/30/2002 | US6379691 Supplying to tissues of vascular system |
| 04/30/2002 | US6378526 Methods of ophthalmic administration |
| 04/30/2002 | CA2358678A1 Heterocyclic derivatives useful as pharmaceutical agents |
| 04/30/2002 | CA2151045C Platelet-activating factor acetylhydrolase |
| 04/30/2002 | CA2042936C Treatment of ocular hypertension with a synergistic combination for ophthalmic use |
| 04/27/2002 | CA2360015A1 Angiotensin i-converting enzyme inhibitory substance |
| 04/25/2002 | WO2002033100A2 Regulation of human adenylate cyclase, type iv |
| 04/25/2002 | WO2002033099A2 Human kinases |
| 04/25/2002 | WO2002033089A2 Ixodes scapularis tissue factor pathway inhibitor |
| 04/25/2002 | WO2002033079A2 Human g-protein coupled receptor and uses thereof |
| 04/25/2002 | WO2002033049A1 Human tuberoinfundibular peptide of 39 residues |
| 04/25/2002 | WO2002032961A2 Novel polypeptides and nucleic acids encoding same |
| 04/25/2002 | WO2002032958A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
| 04/25/2002 | WO2002032953A2 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | WO2002032933A1 Endothelin antagonist |
| 04/25/2002 | WO2002032932A2 Urotensin-ii agonists and antagonists |
| 04/25/2002 | WO2002032902A1 3,8-diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias |
| 04/25/2002 | WO2002032901A2 Bridged piperazine derivatives |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032897A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | WO2002032893A2 Piperidine compounds as anti-allergic |
| 04/25/2002 | WO2002032883A1 Novel 4-benzyloxyphenyl derivative and use thereof |
| 04/25/2002 | WO2002032881A1 Novel remedies or preventives for angiostenosis |
| 04/25/2002 | WO2002032880A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 04/25/2002 | WO2002032879A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 04/25/2002 | WO2002032872A1 Nitrogenous aromatic ring compounds |
| 04/25/2002 | WO2002032864A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | WO2002032861A2 Orally active salts with tyrosine kinase activity |
| 04/25/2002 | WO2002032858A1 Cycloalkylfluorosulfonamide derivatives |
| 04/25/2002 | WO2002032842A2 Compounds with high monoamine transporter affinity |
| 04/25/2002 | WO2002032465A1 Tissue-specific exogenous optical agents |
| 04/25/2002 | WO2002032461A2 Protein c or activated protein c-like molecules |
| 04/25/2002 | WO2002032449A2 Method for treating ischemic events affecting the central nervous system |
| 04/25/2002 | WO2002032447A2 Cell damage inhibitor |
| 04/25/2002 | WO2002032446A2 Use of neutrophil inhibitory factor in combination with other thrombolytic or neuroprotective drugs for treating pathophysiological conditions involving neutrophils |
| 04/25/2002 | WO2002032445A2 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | WO2002032435A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | WO2002032412A2 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
| 04/25/2002 | WO2002032411A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | WO2002032406A2 Methods and products related to pulmonary delivery of polysaccharides |
| 04/25/2002 | WO2002032389A1 Method of treating stroke |
| 04/25/2002 | WO2002032377A2 Estrogen receptor modulators |
| 04/25/2002 | WO2002032373A2 Estrogen receptor modulators |
| 04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/25/2002 | WO2002010137A3 Indazole derivatives as JNK inhibitors |
| 04/25/2002 | WO2002002128A3 Oral compositions comprising antimicrobial agents |
| 04/25/2002 | WO2001097810A3 Use of therapeutic benzamide derivatives |
| 04/25/2002 | WO2001096366A3 Dipeptide inhibitors for the blood-clotting factor xa |
| 04/25/2002 | WO2001093847A3 Compositions, kits, and methods for promoting defined health benefits |
| 04/25/2002 | WO2001093833A3 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 04/25/2002 | WO2001083740A3 Splice-region antisense composition and method |
| 04/25/2002 | WO2001078754A3 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
| 04/25/2002 | WO2001076574A3 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| 04/25/2002 | WO2001072831A3 Immunoregulator |
| 04/25/2002 | WO2001070208A3 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate |
| 04/25/2002 | WO2001068880A3 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 04/25/2002 | WO2001057240A3 Interaction of nmda receptor with protein tyrosine phosphatase |
| 04/25/2002 | WO2001056593A3 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
| 04/25/2002 | WO2001047533A3 INHIBITION OF GSK-3$g(b) |
| 04/25/2002 | WO2001042471A3 Polypeptides and polynucleotides encoding same |
| 04/25/2002 | WO2001002369A3 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 04/25/2002 | US20020049495 Medical device with coating that promotes endothelial cell adherence |
| 04/25/2002 | US20020049389 Noninvasive measurement of chemical substances |
| 04/25/2002 | US20020049329 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them |
| 04/25/2002 | US20020049326 Benzosulfones and related compositions and methods |
| 04/25/2002 | US20020049325 Calcium channel blockers |
| 04/25/2002 | US20020049322 Quinoline and quinazoline compounds useful in therapy |
| 04/25/2002 | US20020049301 For therapy of cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune dieseases cardiovascular diseases, for generating antibodies |
| 04/25/2002 | US20020049255 Method of treating neurodegenerative disorders of the retina and optic nerve head |
| 04/25/2002 | US20020049254 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 04/25/2002 | US20020049251 Wedelolactone and its synthesis for treating neurodegenerative diseases |
| 04/25/2002 | US20020049250 PPAR receptor activator compounds for treating cutaneous disorders/afflictions |
| 04/25/2002 | US20020049247 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes... |
| 04/25/2002 | US20020049244 Treatment of disease or disease symptoms mediated by eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE) a potent constrictor of renal, cerebral and skeletal muscle arterioles |